Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
While it was a costly finding in terms of todays share price, the information gained for the design of the CagriSema High-Dose (7.2 mg semaglutide) and Zenagamtide trials is invaluable
Compelling results from the Phase 2B trial made headlines in December 2025, and now investors are waiting for additional data
Bagsvrd, Denmark: Novo Nordisk A/S
4 Benefits In addition to stimulating insulin release in response to a meal, GLP-1 RAs have demonstrated many other beneficial effects
As a control, DMSO solutions were added instead of the compound
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 22.33
US$ 25.23
US$ 26.57
US$ 28.34
